DLL3: Delta-like protein 3
Inhibits primary neurogenesis.
- Drugs that act on it: 2
- Approved: 1
- In phases 1 to 3: 1
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on DLL3, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
- Antibody-drug conjugate 1
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Tarlatamab | Approved | Amgen | Antibody | Binding agentDelta-like protein 3 binding agent | 38 |
| Rovalpituzumab tesirine | Phase 3 | AbbVie | Antibody-drug conjugate | Binding agentDelta-like protein 3 binding agent | 0 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Spondylocostal dysostosis 1, autosomal recessive
- 0.72
- Small cell lung carcinoma
- 0.59
- Autosomal recessive spondylocostal dysostosis
- 0.53
- Neurodegenerative disease
- 0.53
- Cancer
- 0.46
- Neoplasm
- 0.42
- Hereditary disease
- 0.42
- Spondylocostal dysostosis
- 0.38
- Leukodystrophy and acquired microcephaly with or without dystonia;
- 0.34
- Rib fusion
- 0.34
- Hemivertebrae
- 0.34
- Neuroendocrine carcinoma
- 0.32
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4630888, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q9NYJ7, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets